In an open-label TUXEDO-1 study (NCT04752059), transtuzumab-deruxtecan has shown a high intracranial response rate in patients who have active brain metastases from HER2-positive breast cancer, and it is worth considering as a therapy alternative in this context [34]. Here, ERBB2 is linked to breast carcinoma.